Literature DB >> 588478

Binding of thrombin to functionally defective platelets: a hypothesis on the nature of the thrombin receptor.

P Ganguly.   

Abstract

The initial step in the interaction of thrombin with human platelets is binding of thrombin to specific structures on the platelet surface. Data are presented which show that platelets from thrombasthenic patients bind thrombin similar to controls. In contrast, platelets from a patient with Bernard-Soulier syndrome had lower thrombin binding capacity. It is suggested that glycoprotein one (GP-I) on the platelet surface might be the receptor for thrombin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 588478

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Variant Bernard-Soulier syndrome type bolzano. A congenital bleeding disorder due to a structural and functional abnormality of the platelet glycoprotein Ib-IX complex.

Authors:  L De Marco; M Mazzucato; F Fabris; D De Roia; P Coser; A Girolami; V Vicente; Z M Ruggeri
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

2.  Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis.

Authors:  K J Clemetson; J L McGregor; E James; M Dechavanne; E F Lüscher
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

3.  Human platelet glycoprotein IX: an adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures.

Authors:  M J Hickey; S A Williams; G J Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Analysis of the glycoprotein and protein composition of Bernard-Soulier platelets by single and two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  A T Nurden; D Dupuis; T J Kunicki; J P Caen
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.